Your browser is no longer supported. Please, upgrade your browser.
BCDA BioCardia, Inc. daily Stock Chart
BioCardia, Inc.
Index- P/E- EPS (ttm)-2.59 Insider Own12.20% Shs Outstand6.83M Perf Week4.62%
Market Cap32.86M Forward P/E- EPS next Y-0.64 Insider Trans42.16% Shs Float6.56M Perf Month14.29%
Income-15.60M PEG- EPS next Q-0.23 Inst Own4.70% Short Float0.77% Perf Quarter-34.30%
Sales0.50M P/S65.72 EPS this Y20.60% Inst Trans141.85% Short Ratio0.25 Perf Half Y-46.67%
Book/sh-0.19 P/B- EPS next Y40.70% ROA-245.70% Target Price- Perf Year-68.48%
Cash/sh0.22 P/C12.64 EPS next 5Y- ROE- 52W Range2.01 - 7.25 Perf YTD-26.09%
Dividend- P/FCF- EPS past 5Y- ROI-613.90% 52W High-62.48% Beta1.91
Dividend %- Quick Ratio0.70 Sales past 5Y10.70% Gross Margin52.00% 52W Low35.32% ATR0.18
Employees20 Current Ratio0.70 Sales Q/Q-82.40% Oper. Margin- RSI (14)51.19 Volatility7.01% 6.73%
OptionableNo Debt/Eq- EPS Q/Q11.10% Profit Margin- Rel Volume1.73 Prev Close2.73
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume199.88K Price2.72
Recom2.00 SMA207.96% SMA50-5.32% SMA200-26.94% Volume341,109 Change-0.55%
Aug-05-20 11:15AM  
Jul-22-20 06:51AM  
Jul-01-20 10:20AM  
Jun-29-20 08:00AM  
Jun-17-20 08:30AM  
May-15-20 08:00AM  
May-05-20 07:00AM  
Apr-30-20 08:00AM  
Apr-28-20 03:08PM  
Apr-14-20 08:00AM  
Apr-09-20 02:03PM  
Apr-02-20 08:00AM  
Mar-31-20 08:00AM  
Mar-29-20 08:58AM  
Mar-12-20 08:00AM  
Feb-13-20 06:30AM  
Jan-14-20 08:00AM  
Jan-08-20 08:00AM  
Dec-30-19 10:40AM  
Nov-19-19 05:24PM  
Nov-11-19 07:44AM  
Oct-28-19 08:00AM  
Oct-08-19 08:00AM  
Oct-02-19 08:00AM  
Oct-01-19 08:00AM  
Sep-16-19 08:00AM  
Aug-21-19 08:00AM  
Aug-08-19 08:30AM  
Aug-06-19 04:05PM  
Aug-02-19 09:45AM  
Jul-25-19 06:00AM  
Jun-12-19 08:00AM  
Jun-06-19 08:00AM  
May-23-19 03:23PM  
May-20-19 08:00AM  
May-08-19 08:00AM  
Apr-02-19 08:00AM  
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Allen Jim L.DirectorJun 19Buy2.10142,850299,985668,200Jun 23 09:22 PM
STERTZER SIMON HDirectorJun 19Buy2.10142,850299,985187,983Jun 23 09:21 PM
Blank Andrew ScottDirectorJun 19Buy2.10142,850299,985142,850Jun 23 09:22 PM
Altman PeterPresident and CEOMar 24Buy2.901,2003,480171,911Mar 26 05:30 PM
Altman PeterPresident and CEOMar 19Buy2.954001,180170,711Mar 23 07:30 AM
Altman PeterPresident and CEOMar 18Buy2.533,3008,349170,311Mar 19 04:02 PM
Altman PeterPresident and CEOMar 17Buy3.66200732167,011Mar 19 04:02 PM
Altman PeterPresident and CEOMar 12Buy3.153,40010,710166,811Mar 16 06:09 AM
Altman PeterPresident and CEODec 31Buy3.674,00014,676163,411Jan 03 03:51 PM